We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug News
    • Trending
    • Commercial Operations
    • GMPs
    • FDA Enforcement Actions
    • Inspections and Audits
    • Postmarket Safety
    • Quality
    • Regulatory Affairs
    • Research and Development
    • Submissions and Approvals
    • FDAnews Drug Weekly
    • FDAnews
  • Device News
    • Trending
    • Commercial Operations
    • FDA Enforcement Actions
    • Inspections and Audits
    • Postmarket Safety
    • Quality
    • Regulatory Affairs
    • Research and Development
    • Submissions and Approvals
    • FDAnews Device Weekly
    • FDAnews
  • Books
    • FDAnews Books Library
    • Drug Books
    • Device Books
  • Training/Events
    • Webinar Training Pass
    • Events
    • Webinar Recordings
  • Resources
    • Form 483s Database
    • FDA Approved Drugs
  • CenterWatch
  • About Us
    • The Company
    • FDAnews Editorial Board
    • Contact Us
  • Advertising
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Six FDA Warning Letters Prompted by High Levels of Lidocaine in OTC Numbing Products

Six FDA Warning Letters Prompted by High Levels of Lidocaine in OTC Numbing Products

March 29, 2024

Six manufacturers of numbing gels, creams and sprays marketed to relieve pain from cosmetic procedures have received FDA Warning Letters for concentrations of lidocaine in their products in excess of the allowance of 4 percent for OTC topical pain relief products.

The products are marketed to relieve pain before, during or after certain cosmetic procedures, such as microdermabrasion, laser hair removal, tattooing and piercing, the FDA said in a news statement.

The agency said it has been warning consumers about the danger of these products since 2009, but it “continues to find potentially dangerous products available online and in retail stores. The FDA is not aware of evidence demonstrating these products are safe.”

To read the whole story, click here to subscribe.

Related Topics

Drugs Inspections and Audits Regulatory Affairs

    Upcoming Events

    • 04Apr

      Managing Data and Documentation for FDA Inspections and Remote Assessments

    • 11Apr

      Integrating Regulatory Intelligence into Supplier Management

    • 14Apr

      MAGI 2024: The Clinical Research Conference

    • 25Apr

      A Masterclass on Effective 483 Responses

    • 14May

      2024 Avoca Quality Consortium Summit

    Featured Products

    • FDA, FTC and DOJ Enforcement of Medical Device Regulations

      FDA, FTC and DOJ Enforcement of Medical Device Regulations

    • Using Real-World Evidence in Drug and Device Submissions

      Using Real-World Evidence in Drug and Device Submissions

    Featured Stories

    • CDER Establishes New Quantitative Medicine Center of Excellence

    • Embracing, Expanding Sterilization Standards Endorsed in FDA Webinar

    • Six FDA Warning Letters Prompted by High Levels of Lidocaine in OTC Numbing Products

    • Comments on Benefit-Risk of Phthalates in Medical Devices Sought by EC

    The Revised ICH E8: A Guide to New Clinical Trial Requirements

    Learn More
    • Drug Products
      • Quality
      • Regulatory Affairs
      • GMPs
      • Inspections and Audits
      • Postmarket Safety
      • Submissions and Approvals
      • Research and Development
      • Commercial Operations
    • Device Products
      • Quality
      • Regulatory Affairs
      • QSR
      • Inspections and Audits
      • Postmarket Safety
      • Submissions and Approvals
      • Research and Development
      • Commercial Operations
    • Clinical Products
      • Trial Design
      • Data Integrity
      • GCP
      • Inspections and Audits
      • Transparency
    • Privacy Policy
    • Do Not Sell or Share My Data
    Footer Logo

    212 Carnegie Center, Suite 301, Princeton, NJ 08540, USA

    Phone 703.538.7600 – Toll free 888.838.5578

    Copyright © 2024. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing